| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Immunologic Deficiency Syndromes | 30 | 2026 | 212 | 6.930 |
Why?
|
| Allergy and Immunology | 10 | 2017 | 30 | 3.180 |
Why?
|
| Severe Combined Immunodeficiency | 9 | 2026 | 108 | 2.160 |
Why?
|
| Genetic Therapy | 8 | 2025 | 711 | 1.380 |
Why?
|
| Tryptases | 2 | 2021 | 17 | 1.320 |
Why?
|
| Mast Cells | 2 | 2021 | 67 | 1.270 |
Why?
|
| DiGeorge Syndrome | 4 | 2011 | 83 | 1.060 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 10 | 2026 | 1275 | 0.910 |
Why?
|
| T-Lymphocytes | 14 | 2022 | 1710 | 0.880 |
Why?
|
| Hypersensitivity | 6 | 2011 | 226 | 0.840 |
Why?
|
| Phospholipase C gamma | 1 | 2024 | 27 | 0.820 |
Why?
|
| HIV Infections | 10 | 2021 | 2040 | 0.780 |
Why?
|
| Immune System Diseases | 3 | 2014 | 55 | 0.710 |
Why?
|
| Urticaria | 1 | 2021 | 19 | 0.680 |
Why?
|
| Mastocytosis, Systemic | 1 | 2020 | 8 | 0.640 |
Why?
|
| Immunotherapy | 5 | 2017 | 759 | 0.640 |
Why?
|
| Hypereosinophilic Syndrome | 1 | 2020 | 8 | 0.640 |
Why?
|
| Granulomatous Disease, Chronic | 5 | 2025 | 70 | 0.600 |
Why?
|
| Phenotype | 5 | 2024 | 4464 | 0.590 |
Why?
|
| Leukemia | 3 | 2020 | 375 | 0.590 |
Why?
|
| Immune System | 2 | 2010 | 99 | 0.560 |
Why?
|
| Humans | 74 | 2026 | 130154 | 0.550 |
Why?
|
| B-Lymphocytes | 8 | 2011 | 511 | 0.540 |
Why?
|
| Disaster Medicine | 1 | 2017 | 9 | 0.540 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2021 | 468 | 0.520 |
Why?
|
| Genetic Testing | 2 | 2026 | 1106 | 0.520 |
Why?
|
| Thiazolidinediones | 1 | 2017 | 81 | 0.500 |
Why?
|
| Cytokines | 6 | 2011 | 1342 | 0.500 |
Why?
|
| Autoimmunity | 3 | 2018 | 175 | 0.490 |
Why?
|
| Cyclonic Storms | 1 | 2017 | 82 | 0.490 |
Why?
|
| rab GTP-Binding Proteins | 1 | 2016 | 50 | 0.490 |
Why?
|
| Wiskott-Aldrich Syndrome | 2 | 2025 | 25 | 0.490 |
Why?
|
| Neonatal Screening | 4 | 2026 | 204 | 0.470 |
Why?
|
| Agammaglobulinemia | 4 | 2025 | 43 | 0.460 |
Why?
|
| DNA Helicases | 1 | 2016 | 234 | 0.450 |
Why?
|
| Killer Cells, Natural | 2 | 2016 | 351 | 0.440 |
Why?
|
| Drug Hypersensitivity | 5 | 2011 | 99 | 0.400 |
Why?
|
| Autoimmune Diseases | 4 | 2011 | 257 | 0.360 |
Why?
|
| Biomedical Research | 1 | 2017 | 556 | 0.350 |
Why?
|
| Transmembrane Activator and CAML Interactor Protein | 1 | 2011 | 3 | 0.340 |
Why?
|
| Immunoglobulins, Intravenous | 5 | 2016 | 148 | 0.340 |
Why?
|
| Anaphylaxis | 2 | 2023 | 91 | 0.340 |
Why?
|
| Physicians | 1 | 2017 | 627 | 0.330 |
Why?
|
| Immunoglobulins | 2 | 2016 | 154 | 0.330 |
Why?
|
| Malnutrition | 4 | 2021 | 156 | 0.330 |
Why?
|
| Biomarkers | 1 | 2020 | 3360 | 0.320 |
Why?
|
| Animals | 18 | 2025 | 33698 | 0.320 |
Why?
|
| Smith-Magenis Syndrome | 1 | 2011 | 107 | 0.320 |
Why?
|
| Immunity | 3 | 2010 | 179 | 0.320 |
Why?
|
| Histocompatibility Antigens | 1 | 2010 | 17 | 0.310 |
Why?
|
| Transplantation Immunology | 1 | 2010 | 40 | 0.310 |
Why?
|
| Bone Marrow Transplantation | 2 | 2010 | 590 | 0.310 |
Why?
|
| Receptors, Interleukin-2 | 2 | 2007 | 37 | 0.310 |
Why?
|
| Immunity, Innate | 3 | 2011 | 410 | 0.310 |
Why?
|
| Infant | 17 | 2023 | 13276 | 0.290 |
Why?
|
| Lymphopenia | 3 | 2023 | 34 | 0.290 |
Why?
|
| Interleukin-7 | 1 | 2009 | 46 | 0.290 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2009 | 118 | 0.290 |
Why?
|
| Antigens, Fungal | 1 | 2008 | 32 | 0.290 |
Why?
|
| CD3 Complex | 3 | 2008 | 95 | 0.280 |
Why?
|
| Tetanus Toxoid | 1 | 2008 | 47 | 0.280 |
Why?
|
| Candida | 1 | 2008 | 79 | 0.270 |
Why?
|
| Down Syndrome | 1 | 2011 | 233 | 0.270 |
Why?
|
| Respiratory Tract Infections | 1 | 2011 | 295 | 0.270 |
Why?
|
| Child, Preschool | 15 | 2023 | 15009 | 0.260 |
Why?
|
| Infant, Newborn | 8 | 2026 | 8551 | 0.260 |
Why?
|
| Receptors, Cell Surface | 2 | 2007 | 420 | 0.260 |
Why?
|
| Organ Transplantation | 1 | 2010 | 171 | 0.260 |
Why?
|
| X-Linked Combined Immunodeficiency Diseases | 1 | 2007 | 3 | 0.260 |
Why?
|
| Graft Rejection | 3 | 2010 | 558 | 0.260 |
Why?
|
| rab27 GTP-Binding Proteins | 2 | 2016 | 5 | 0.250 |
Why?
|
| Antigens, Bacterial | 1 | 2008 | 318 | 0.240 |
Why?
|
| Mastocytosis | 2 | 2021 | 7 | 0.240 |
Why?
|
| Lymphoma, B-Cell | 1 | 2007 | 145 | 0.230 |
Why?
|
| Th1 Cells | 2 | 2005 | 159 | 0.230 |
Why?
|
| Lymphocyte Count | 4 | 2009 | 118 | 0.230 |
Why?
|
| Membrane Proteins | 4 | 2025 | 1588 | 0.230 |
Why?
|
| Vaccines, DNA | 1 | 2005 | 44 | 0.230 |
Why?
|
| Environment | 2 | 2021 | 148 | 0.220 |
Why?
|
| Exodeoxyribonucleases | 1 | 2025 | 51 | 0.220 |
Why?
|
| Autoimmune Diseases of the Nervous System | 1 | 2025 | 38 | 0.220 |
Why?
|
| Child | 17 | 2023 | 26181 | 0.210 |
Why?
|
| Arthropod Venoms | 1 | 2023 | 8 | 0.200 |
Why?
|
| Ants | 1 | 2023 | 7 | 0.200 |
Why?
|
| High-Throughput Nucleotide Sequencing | 3 | 2017 | 891 | 0.200 |
Why?
|
| Nervous System Malformations | 1 | 2025 | 136 | 0.200 |
Why?
|
| Adolescent | 9 | 2021 | 20802 | 0.200 |
Why?
|
| Insect Bites and Stings | 1 | 2023 | 42 | 0.190 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2023 | 57 | 0.190 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2017 | 613 | 0.190 |
Why?
|
| Phosphoproteins | 1 | 2025 | 448 | 0.190 |
Why?
|
| Precision Medicine | 1 | 2026 | 383 | 0.190 |
Why?
|
| Immunosuppressive Agents | 2 | 2021 | 655 | 0.190 |
Why?
|
| Male | 19 | 2024 | 64397 | 0.190 |
Why?
|
| Wounds and Injuries | 2 | 2021 | 389 | 0.180 |
Why?
|
| Signal Transduction | 4 | 2009 | 4656 | 0.180 |
Why?
|
| Skin Diseases | 2 | 2022 | 142 | 0.180 |
Why?
|
| Gene Editing | 1 | 2025 | 237 | 0.180 |
Why?
|
| Clinical Trials as Topic | 4 | 2017 | 1121 | 0.180 |
Why?
|
| Cell Proliferation | 2 | 2010 | 2463 | 0.180 |
Why?
|
| Mutation | 7 | 2024 | 6070 | 0.180 |
Why?
|
| Candidiasis, Chronic Mucocutaneous | 1 | 2021 | 5 | 0.180 |
Why?
|
| Recombinant Fusion Proteins | 3 | 2009 | 690 | 0.180 |
Why?
|
| Genetic Vectors | 2 | 2025 | 893 | 0.180 |
Why?
|
| Cetirizine | 1 | 2021 | 4 | 0.170 |
Why?
|
| Anemia, Sideroblastic | 1 | 2021 | 15 | 0.170 |
Why?
|
| HIV-1 | 3 | 2001 | 494 | 0.170 |
Why?
|
| Anti-Allergic Agents | 1 | 2021 | 28 | 0.170 |
Why?
|
| Twins, Monozygotic | 1 | 2021 | 124 | 0.160 |
Why?
|
| Gene Products, tat | 3 | 1997 | 27 | 0.160 |
Why?
|
| HIV | 2 | 2002 | 174 | 0.160 |
Why?
|
| Antibody Formation | 4 | 2010 | 226 | 0.160 |
Why?
|
| Metabolism, Inborn Errors | 1 | 2021 | 125 | 0.160 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2021 | 218 | 0.160 |
Why?
|
| Phenobarbital | 1 | 2000 | 30 | 0.160 |
Why?
|
| Opportunistic Infections | 2 | 2015 | 72 | 0.160 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2007 | 501 | 0.160 |
Why?
|
| Metabolic Diseases | 1 | 2021 | 140 | 0.150 |
Why?
|
| Transcription Factors | 2 | 2007 | 2404 | 0.150 |
Why?
|
| Antibodies, Monoclonal | 3 | 2011 | 979 | 0.150 |
Why?
|
| Immunologic Factors | 2 | 2011 | 189 | 0.150 |
Why?
|
| Female | 17 | 2024 | 70285 | 0.150 |
Why?
|
| NF-kappa B p50 Subunit | 1 | 2018 | 10 | 0.140 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2022 | 499 | 0.140 |
Why?
|
| Thymectomy | 1 | 2018 | 24 | 0.140 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2018 | 71 | 0.140 |
Why?
|
| Quality of Life | 3 | 2026 | 2072 | 0.140 |
Why?
|
| Dendritic Cells | 3 | 2008 | 435 | 0.140 |
Why?
|
| Gene Products, rev | 2 | 1997 | 11 | 0.140 |
Why?
|
| Splenectomy | 1 | 2018 | 61 | 0.140 |
Why?
|
| Angioedema | 2 | 2009 | 21 | 0.140 |
Why?
|
| Puerto Rico | 1 | 2017 | 54 | 0.140 |
Why?
|
| Antiretroviral Therapy, Highly Active | 2 | 2009 | 256 | 0.130 |
Why?
|
| Immunity, Humoral | 3 | 2016 | 73 | 0.130 |
Why?
|
| Diagnosis, Differential | 2 | 2020 | 1872 | 0.130 |
Why?
|
| Immunization, Passive | 2 | 2009 | 122 | 0.130 |
Why?
|
| Practice Guidelines as Topic | 3 | 2020 | 1282 | 0.130 |
Why?
|
| Genetic Variation | 1 | 2024 | 1542 | 0.130 |
Why?
|
| Anticonvulsants | 1 | 2000 | 362 | 0.130 |
Why?
|
| T-Lymphocyte Subsets | 2 | 2009 | 196 | 0.130 |
Why?
|
| AIDS Vaccines | 2 | 2009 | 33 | 0.120 |
Why?
|
| Genomics | 2 | 2022 | 1618 | 0.120 |
Why?
|
| Toll-Like Receptors | 2 | 2007 | 83 | 0.120 |
Why?
|
| Microfilament Proteins | 1 | 2017 | 269 | 0.110 |
Why?
|
| Cohort Studies | 3 | 2011 | 5042 | 0.110 |
Why?
|
| Immunoglobulin G | 3 | 2009 | 792 | 0.110 |
Why?
|
| Prenatal Diagnosis | 1 | 2019 | 611 | 0.110 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2017 | 484 | 0.110 |
Why?
|
| Disease Management | 2 | 2015 | 555 | 0.110 |
Why?
|
| Prognosis | 2 | 2020 | 4848 | 0.100 |
Why?
|
| History, 21st Century | 1 | 2015 | 259 | 0.100 |
Why?
|
| CD4 Antigens | 2 | 2003 | 53 | 0.100 |
Why?
|
| Repressor Proteins | 1 | 2017 | 757 | 0.100 |
Why?
|
| Common Variable Immunodeficiency | 2 | 2011 | 31 | 0.100 |
Why?
|
| Pneumococcal Vaccines | 2 | 2012 | 174 | 0.100 |
Why?
|
| Leukocyte-Adhesion Deficiency Syndrome | 1 | 2012 | 3 | 0.090 |
Why?
|
| Hypersensitivity, Immediate | 1 | 2012 | 31 | 0.090 |
Why?
|
| Unrelated Donors | 1 | 2011 | 72 | 0.090 |
Why?
|
| Mutation, Missense | 1 | 2016 | 922 | 0.090 |
Why?
|
| Cytidine Deaminase | 1 | 2011 | 31 | 0.090 |
Why?
|
| Toll-Like Receptor 9 | 1 | 2011 | 22 | 0.090 |
Why?
|
| Angioedemas, Hereditary | 1 | 2011 | 6 | 0.080 |
Why?
|
| Models, Immunological | 1 | 2011 | 35 | 0.080 |
Why?
|
| Injections, Subcutaneous | 2 | 2016 | 135 | 0.080 |
Why?
|
| Lymphocyte Subsets | 1 | 2011 | 40 | 0.080 |
Why?
|
| Immunoglobulin Isotypes | 1 | 2010 | 14 | 0.080 |
Why?
|
| Antibody-Producing Cells | 1 | 2010 | 5 | 0.080 |
Why?
|
| Immunity, Cellular | 2 | 2008 | 197 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2021 | 3407 | 0.080 |
Why?
|
| Genes, X-Linked | 1 | 2010 | 60 | 0.080 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 1 | 2009 | 18 | 0.080 |
Why?
|
| Haploinsufficiency | 1 | 2011 | 265 | 0.070 |
Why?
|
| Immune Tolerance | 1 | 2010 | 153 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2011 | 363 | 0.070 |
Why?
|
| Young Adult | 3 | 2016 | 9987 | 0.070 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 2008 | 33 | 0.070 |
Why?
|
| RNA, Messenger | 2 | 2012 | 2553 | 0.070 |
Why?
|
| Complement System Proteins | 2 | 2005 | 58 | 0.070 |
Why?
|
| Lymphocyte Depletion | 1 | 2008 | 124 | 0.070 |
Why?
|
| Forkhead Transcription Factors | 1 | 2011 | 373 | 0.070 |
Why?
|
| Base Sequence | 2 | 2011 | 2729 | 0.070 |
Why?
|
| Antigen Presentation | 1 | 2008 | 111 | 0.070 |
Why?
|
| Neoplasm Proteins | 1 | 2012 | 679 | 0.070 |
Why?
|
| Tissue Donors | 1 | 2011 | 506 | 0.070 |
Why?
|
| Chromosome Deletion | 1 | 2011 | 654 | 0.070 |
Why?
|
| Uremia | 1 | 2008 | 33 | 0.070 |
Why?
|
| Transplantation Conditioning | 1 | 2009 | 327 | 0.070 |
Why?
|
| Complement C1 Inhibitor Protein | 1 | 2007 | 7 | 0.070 |
Why?
|
| Antigens, CD1d | 1 | 2007 | 20 | 0.070 |
Why?
|
| Antigens, CD1 | 1 | 2007 | 23 | 0.070 |
Why?
|
| Immunoglobulin E | 1 | 2008 | 215 | 0.060 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2023 | 219 | 0.060 |
Why?
|
| Adult | 5 | 2016 | 31042 | 0.060 |
Why?
|
| Homeodomain Proteins | 1 | 2010 | 558 | 0.060 |
Why?
|
| NADPH Oxidases | 2 | 2022 | 109 | 0.060 |
Why?
|
| Membrane Glycoproteins | 2 | 2010 | 407 | 0.060 |
Why?
|
| Vaccination | 1 | 2012 | 1056 | 0.060 |
Why?
|
| Antigens, CD | 1 | 2008 | 411 | 0.060 |
Why?
|
| Retroviridae | 1 | 2007 | 182 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 1 | 2010 | 1454 | 0.060 |
Why?
|
| Transplantation, Autologous | 1 | 2007 | 253 | 0.060 |
Why?
|
| Neck | 1 | 2007 | 140 | 0.060 |
Why?
|
| Gamma Rays | 1 | 2006 | 38 | 0.060 |
Why?
|
| Diabetes Complications | 1 | 2008 | 197 | 0.060 |
Why?
|
| Neoplasms | 1 | 2021 | 2980 | 0.060 |
Why?
|
| Antibodies, Bacterial | 1 | 2008 | 417 | 0.060 |
Why?
|
| Transduction, Genetic | 1 | 2007 | 277 | 0.060 |
Why?
|
| Respiratory System | 1 | 2006 | 95 | 0.060 |
Why?
|
| Infection Control | 1 | 2007 | 156 | 0.060 |
Why?
|
| Cell Line | 3 | 2012 | 2554 | 0.060 |
Why?
|
| Surgical Procedures, Operative | 1 | 2008 | 225 | 0.060 |
Why?
|
| Cloning, Molecular | 2 | 1997 | 778 | 0.050 |
Why?
|
| Antarctic Regions | 1 | 2004 | 8 | 0.050 |
Why?
|
| Adenosine Deaminase | 1 | 2004 | 89 | 0.050 |
Why?
|
| Self Administration | 1 | 2004 | 49 | 0.050 |
Why?
|
| Th2 Cells | 1 | 2005 | 188 | 0.050 |
Why?
|
| Substrate Specificity | 1 | 2025 | 284 | 0.050 |
Why?
|
| Prevalence | 1 | 2011 | 2685 | 0.050 |
Why?
|
| Allergens | 1 | 2007 | 344 | 0.050 |
Why?
|
| Inflammation | 1 | 2011 | 1481 | 0.050 |
Why?
|
| Chromosomes, Human, X | 1 | 2004 | 154 | 0.050 |
Why?
|
| Proteolysis | 1 | 2025 | 198 | 0.050 |
Why?
|
| Trichosporon | 1 | 2003 | 4 | 0.050 |
Why?
|
| ZAP-70 Protein-Tyrosine Kinase | 1 | 2023 | 13 | 0.050 |
Why?
|
| src Homology Domains | 1 | 2023 | 34 | 0.050 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2009 | 776 | 0.050 |
Why?
|
| Phytohemagglutinins | 1 | 2003 | 12 | 0.050 |
Why?
|
| Nucleoside Deaminases | 1 | 2003 | 23 | 0.050 |
Why?
|
| Cytosine Deaminase | 1 | 2003 | 15 | 0.050 |
Why?
|
| Busulfan | 1 | 2023 | 51 | 0.050 |
Why?
|
| CD8 Antigens | 1 | 2003 | 39 | 0.050 |
Why?
|
| Liver Transplantation | 1 | 2012 | 1136 | 0.050 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2003 | 71 | 0.050 |
Why?
|
| Injections, Intravenous | 1 | 2003 | 237 | 0.050 |
Why?
|
| Respiratory Burst | 1 | 2022 | 8 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2012 | 5161 | 0.050 |
Why?
|
| HEK293 Cells | 1 | 2025 | 802 | 0.050 |
Why?
|
| tat Gene Products, Human Immunodeficiency Virus | 3 | 1997 | 32 | 0.050 |
Why?
|
| Evidence-Based Medicine | 2 | 2016 | 641 | 0.050 |
Why?
|
| Vaccines | 1 | 2007 | 385 | 0.050 |
Why?
|
| Amino Acid Substitution | 2 | 2016 | 404 | 0.050 |
Why?
|
| Mycoses | 1 | 2003 | 110 | 0.050 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2025 | 228 | 0.040 |
Why?
|
| RNA Splice Sites | 1 | 2022 | 91 | 0.040 |
Why?
|
| Cell Communication | 1 | 2003 | 188 | 0.040 |
Why?
|
| T-Box Domain Proteins | 1 | 2003 | 123 | 0.040 |
Why?
|
| United States | 1 | 2017 | 11885 | 0.040 |
Why?
|
| Retrospective Studies | 4 | 2012 | 17554 | 0.040 |
Why?
|
| CARD Signaling Adaptor Proteins | 1 | 2021 | 43 | 0.040 |
Why?
|
| Reference Values | 1 | 2003 | 674 | 0.040 |
Why?
|
| Cell Division | 1 | 2003 | 718 | 0.040 |
Why?
|
| Nucleotidyltransferases | 1 | 2021 | 47 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2023 | 6403 | 0.040 |
Why?
|
| Virus Replication | 2 | 2002 | 607 | 0.040 |
Why?
|
| Cyclophosphamide | 1 | 2023 | 426 | 0.040 |
Why?
|
| Arginine | 1 | 2023 | 336 | 0.040 |
Why?
|
| Graft vs Host Disease | 3 | 2011 | 688 | 0.040 |
Why?
|
| Cytopathogenic Effect, Viral | 2 | 1997 | 27 | 0.040 |
Why?
|
| rev Gene Products, Human Immunodeficiency Virus | 2 | 1997 | 15 | 0.040 |
Why?
|
| Gene Dosage | 1 | 2021 | 435 | 0.040 |
Why?
|
| Lymphocyte Activation | 2 | 2000 | 634 | 0.040 |
Why?
|
| Homozygote | 1 | 2021 | 534 | 0.040 |
Why?
|
| Postoperative Complications | 1 | 2012 | 3113 | 0.040 |
Why?
|
| Treatment Outcome | 4 | 2011 | 12843 | 0.040 |
Why?
|
| Space Flight | 1 | 2003 | 176 | 0.040 |
Why?
|
| Reactive Oxygen Species | 1 | 2022 | 526 | 0.040 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 1 | 2000 | 78 | 0.040 |
Why?
|
| Primary Health Care | 1 | 2005 | 768 | 0.040 |
Why?
|
| Fever | 1 | 2021 | 313 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2003 | 1485 | 0.040 |
Why?
|
| Genes, tat | 2 | 1995 | 10 | 0.030 |
Why?
|
| Genome, Human | 1 | 2005 | 1315 | 0.030 |
Why?
|
| Alleles | 1 | 2021 | 1675 | 0.030 |
Why?
|
| Piebaldism | 1 | 2016 | 3 | 0.030 |
Why?
|
| Immunomodulation | 1 | 2016 | 85 | 0.030 |
Why?
|
| Albinism | 1 | 2016 | 8 | 0.030 |
Why?
|
| Consanguinity | 1 | 2016 | 115 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 1997 | 354 | 0.030 |
Why?
|
| HeLa Cells | 1 | 1997 | 689 | 0.030 |
Why?
|
| Genes, rev | 1 | 1995 | 5 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2003 | 1910 | 0.030 |
Why?
|
| Genes, Recessive | 1 | 2016 | 194 | 0.030 |
Why?
|
| Amino Acid Sequence | 3 | 2012 | 2390 | 0.030 |
Why?
|
| Advisory Committees | 1 | 2015 | 148 | 0.030 |
Why?
|
| Cells, Cultured | 2 | 1997 | 2887 | 0.030 |
Why?
|
| Molecular Sequence Data | 3 | 2012 | 3463 | 0.030 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2016 | 158 | 0.030 |
Why?
|
| Bacteriophage phi X 174 | 1 | 2012 | 4 | 0.020 |
Why?
|
| Rabies Vaccines | 1 | 2012 | 12 | 0.020 |
Why?
|
| Salmonella Vaccines | 1 | 2012 | 7 | 0.020 |
Why?
|
| Gene Expression | 1 | 1997 | 1481 | 0.020 |
Why?
|
| Haemophilus Vaccines | 1 | 2012 | 33 | 0.020 |
Why?
|
| Bacterial Capsules | 1 | 2012 | 42 | 0.020 |
Why?
|
| Pedigree | 1 | 2016 | 1672 | 0.020 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2012 | 115 | 0.020 |
Why?
|
| Protein Binding | 1 | 2016 | 1650 | 0.020 |
Why?
|
| Sibling Relations | 1 | 2011 | 12 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2012 | 189 | 0.020 |
Why?
|
| Antibodies | 1 | 2012 | 317 | 0.020 |
Why?
|
| DNA Copy Number Variations | 1 | 2016 | 1026 | 0.020 |
Why?
|
| Codon | 1 | 2010 | 92 | 0.020 |
Why?
|
| B-Cell Activating Factor | 1 | 2010 | 4 | 0.020 |
Why?
|
| Educational Status | 1 | 2011 | 276 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2012 | 1013 | 0.020 |
Why?
|
| NADPH Oxidase 2 | 1 | 2010 | 38 | 0.020 |
Why?
|
| Cell Migration Inhibition | 1 | 2009 | 8 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2012 | 766 | 0.020 |
Why?
|
| Mice | 2 | 2021 | 18172 | 0.020 |
Why?
|
| Genetic Diseases, X-Linked | 1 | 2010 | 84 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2011 | 668 | 0.020 |
Why?
|
| Immunophenotyping | 1 | 2010 | 331 | 0.020 |
Why?
|
| Delayed Diagnosis | 1 | 2011 | 130 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2010 | 354 | 0.020 |
Why?
|
| Activities of Daily Living | 1 | 2011 | 388 | 0.020 |
Why?
|
| Complementary Therapies | 1 | 2009 | 45 | 0.020 |
Why?
|
| Spleen | 1 | 2010 | 258 | 0.020 |
Why?
|
| Academies and Institutes | 1 | 2009 | 81 | 0.020 |
Why?
|
| Immunization | 1 | 2010 | 268 | 0.020 |
Why?
|
| Immunoglobulin A | 1 | 2009 | 204 | 0.020 |
Why?
|
| Pregnancy | 1 | 2001 | 7396 | 0.020 |
Why?
|
| Inflammation Mediators | 1 | 2009 | 228 | 0.020 |
Why?
|
| Drug Discovery | 1 | 2009 | 177 | 0.020 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2008 | 215 | 0.020 |
Why?
|
| Autoantibodies | 1 | 2010 | 436 | 0.020 |
Why?
|
| Risk Factors | 1 | 2001 | 10953 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2009 | 1070 | 0.020 |
Why?
|
| Graft Survival | 1 | 2008 | 466 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2008 | 902 | 0.020 |
Why?
|
| Phagocyte Bactericidal Dysfunction | 1 | 2005 | 1 | 0.010 |
Why?
|
| Age Factors | 1 | 2012 | 2823 | 0.010 |
Why?
|
| Luciferases | 2 | 1995 | 126 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2010 | 1692 | 0.010 |
Why?
|
| Risk | 1 | 2006 | 723 | 0.010 |
Why?
|
| Cytomegalovirus Infections | 1 | 2006 | 221 | 0.010 |
Why?
|
| Communicable Diseases | 1 | 2006 | 159 | 0.010 |
Why?
|
| Survival Rate | 1 | 2008 | 2112 | 0.010 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2006 | 395 | 0.010 |
Why?
|
| Nervous System Diseases | 1 | 2006 | 393 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2012 | 4032 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2010 | 4693 | 0.010 |
Why?
|
| Kidney Transplantation | 1 | 2006 | 552 | 0.010 |
Why?
|
| Time Factors | 1 | 2008 | 6178 | 0.010 |
Why?
|
| Algorithms | 1 | 2005 | 1661 | 0.010 |
Why?
|
| Mental Disorders | 1 | 2006 | 898 | 0.010 |
Why?
|
| Aged | 1 | 2016 | 20833 | 0.010 |
Why?
|
| Asthma | 1 | 2006 | 921 | 0.010 |
Why?
|
| Middle Aged | 1 | 2016 | 28331 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2003 | 2058 | 0.010 |
Why?
|
| Genes, Dominant | 1 | 1995 | 242 | 0.010 |
Why?
|
| Zidovudine | 1 | 1994 | 22 | 0.010 |
Why?
|
| Transfection | 1 | 1995 | 961 | 0.010 |
Why?
|
| DNA Primers | 1 | 1994 | 600 | 0.010 |
Why?
|
| Sequence Deletion | 1 | 1995 | 517 | 0.010 |
Why?
|